| Business Summary | | Gilead
Sciences,
Inc.
is
an
independent
biopharmaceutical
company
that
seeks
to
provide
accelerated
solutions
for
patients
and
the
people
who
care
for
them.
The
Company
discovers,
develops,
manufactures
and
commercializes
proprietary
therapeutics
for
challenging
infectious
diseases
(viral,
fungal
and
bacterial
infections)
and
cancer.
Gilead
also
has
expertise
in
liposomal
drug
delivery
technology.
Currently,
the
Company
markets
AmBisome
((amphotericin
B)
liposome
for
injection),
an
antifungal
agent,
DaunoXome
(daunorubicin
citrate
liposome
injection),
a
drug
approved
for
the
treatment
of
Kaposi's
Sarcoma,
and
VISTIDE
(cidofovir
injection)
for
the
treatment
of
cytomegalovirus
(CMV)
retinitis.
Hoffmann-La
Roche,
Inc.
markets
Tamiflu
(oseltamivir
phosphate)
for
the
treatment
of
influenza,
under
a
collaborative
agreement
with
Gilead.
In
addition,
Gilead
is
developing
products
to
treat
diseases
caused
by
human
immunodeficiency
virus
and
hepatitis
B
virus,
bacterial
infections
and
cancer. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Gilead
Sciences,
Inc.
provide
accelerated
solutions
for
patients
and
caretakers
with
a
focus
on
developing
and
marketing
drugs
to
treat
patients
with
infectious
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
11%
to
$108.5
million.
Net
loss
before
accounting
change
totaled
$55.2
million,
up
from
$7.3
million.
Revenues
reflect
increased
product
sales.
Earnings
were
offset
by
an
up-front
license
fee
paid
to
Cubist
for
the
daptomycin
licensing
agreement. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Denny, 68 Chairman | -- | -- | John Martin, Ph.D., 49 Pres,
CEO, Director | $534K | $4.1M | Sharon Surrey-Barbari, 46 CFO,
VP | -- | -- | Norbert Bischofberger, Ph.D., 45 Exec.
VP of R&D | 365K | 2.3M | Mark Perry, 45 Exec.
VP, Operations | 350K | 4.1M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|